Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
$0.62
-1.7%		$0.56
$0.43
▼
$2.04
$11.65M-2.7313.58 million shs427,168 shs
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
$1.48
-5.7%		$1.31
$1.00
▼
$2.23
$18.49M1.662.62 million shs383,335 shs
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$8.34
+2.6%		$7.38
$3.75
▼
$9.40
$37.01M1.517,077 shs15,468 shs
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
$0.20
-5.3%		$0.29
$0.19
▼
$3.54
$3.44M1.49920,590 shs707,306 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
-1.72%-7.23%+25.76%-11.77%-57.41%
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
-5.73%-10.84%+16.54%+28.70%-14.94%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
+2.58%+4.77%+1.71%+35.61%+86.24%
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
-5.35%-12.32%-29.81%-79.96%-93.88%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
$0.62
-1.7%		$0.56
$0.43
▼
$2.04
$11.65M-2.7313.58 million shs427,168 shs
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
$1.48
-5.7%		$1.31
$1.00
▼
$2.23
$18.49M1.662.62 million shs383,335 shs
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$8.34
+2.6%		$7.38
$3.75
▼
$9.40
$37.01M1.517,077 shs15,468 shs
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
$0.20
-5.3%		$0.29
$0.19
▼
$3.54
$3.44M1.49920,590 shs707,306 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
-1.72%-7.23%+25.76%-11.77%-57.41%
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
-5.73%-10.84%+16.54%+28.70%-14.94%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
+2.58%+4.77%+1.71%+35.61%+86.24%
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
-5.35%-12.32%-29.81%-79.96%-93.88%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
1.50
ReduceN/AN/A
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
2.00
Hold$6.00305.41% Upside
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
2.00
Hold$6.75-19.06% Downside
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest BFRG, HBIO, BNGO, and VIVS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/16/2026
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
9/2/2026
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E) ➝ Sell (E+)
8/19/2026
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
8/18/2026
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (E+) ➝ Sell (E)
8/14/2026
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/12/2026
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
Benchmark Co. logo
Benchmark
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetSpeculative Buy$6.00 ➝ $7.50
8/3/2026
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/29/2026
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
$120K95.40N/AN/A$0.19 per share3.25
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
$30.18M0.58N/AN/A$4.37 per share0.34
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$86.55M0.44$12.09 per share0.69$3.07 per share2.72
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
$130K25.06N/AN/A($0.42) per share-0.47
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
-$6.50M-$0.46N/AN/AN/AN/A-150.36%-127.98%11/13/2026 (Estimated)
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
-$26.40M-$3.02N/AN/AN/A-106.58%-78.78%-48.54%10/29/2026 (Estimated)
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
-$56.70M-$2.31N/AN/AN/A-11.86%-33.13%-4.80%11/5/2026 (Estimated)
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
-$13.84M-$4.47N/AN/AN/A-11,016.07%-612.23%-177.02%N/A

Latest BFRG, HBIO, BNGO, and VIVS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
-$0.11-$0.07+$0.04-$0.07$0.22 million$0.22 million
8/12/2026Q1 2027
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
N/A-$0.25N/A-$0.25N/A$0.02 million
8/11/2026Q2 2026
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
-$0.21-$0.14+$0.07-$0.64$21.45 million$22.73 million
8/10/2026Q2 2026
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
-$0.67-$0.64+$0.03-$0.64$7.55 million($6.67) million
7/14/2026Q4 2026
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
N/A-$2.21N/A-$2.21N/A$0.04 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
N/AN/AN/AN/AN/A
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
N/AN/AN/AN/AN/A
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
N/AN/AN/AN/AN/A
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
N/A
10.57
10.57
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
0.11
2.48
1.96
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
4.94
1.87
0.98
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
N/A
1.70
1.70

Institutional Ownership

CompanyInstitutional Ownership
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
0.96%
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
11.35%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
80.87%
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
8.23%

Insider Ownership

CompanyInsider Ownership
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
14.70%
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
0.65%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
17.03%
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
1718.54 million15.82 millionNot Optionable
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
9711.78 million11.70 millionNo Data
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
3394.55 million3.78 millionNo Data
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
1116.59 million16.42 millionN/A

Recent News About These Companies

Analyzing iSpecimen (NASDAQ:ISPC) & VivoSim Labs (NASDAQ:VIVS)
October 2 at 5:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31078076
VivoSim Labs Inc. (NASDAQ: VIVS) Targets the Multibillion-Dollar Cost of Failed Drugs
September 28, 2026  |  financialcontent.comF
Critical Survey: Bio-Techne (NASDAQ:TECH) versus VivoSim Labs (NASDAQ:VIVS)
September 27, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31054916
Analyzing Quantum-Si (NASDAQ:QSI) & VivoSim Labs (NASDAQ:VIVS)
September 24, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31044317
VivoSim Labs Inc. (NASDAQ: VIVS) Uses Human 3D Biology to Streamline Drug Development
September 23, 2026  |  marketscreener.comM
Critical Review: VivoSim Labs (NASDAQ:VIVS) and Caris Life Sciences (NASDAQ:CAI)
September 22, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31039391
VivoSim Labs Inc. (NASDAQ: VIVS) Takes Aim at Pharma’s 92% Drug-Failure Problem
September 21, 2026  |  financialcontent.comF
High-Impact Stocks DRK, VIVS, AEMD, GMG in the News
September 17, 2026  |  financialcontent.comF
VivoSim Labs Presents New NAMkind Data At EUROTOX 2026
September 16, 2026  |  rttnews.comhttps://www.rttnews.com/3691506/vivosim-labs-presents-new-namkind-data-at-eurotox-2026.aspx
VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
September 16, 2026  |  financialpost.comF
VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
September 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/16/3363138/37000/en/vivosim-labs-unveils-new-namkind-drug-toxicity-data-at-eurotox-2026-demonstrating-predictive-superiority-in-liver-and-gastrointestinal-safety-across-small-molecules-and-adcs.html
VivoSim Labs to Add Rat Liver Model to NAMkind Platform
September 1, 2026  |  financialpost.comF
VivoSim Labs to Add Rat Liver Model to NAMkind Platform
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354127/37000/en/vivosim-labs-to-add-rat-liver-model-to-namkind-platform.html
VivoSim Provides Financial and Listing Compliance Update
August 6, 2026  |  financialpost.comF
VivoSim Provides Financial and Listing Compliance Update
August 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/06/3340246/37000/en/vivosim-provides-financial-and-listing-compliance-update.html
VivoSim Labs Sets 2026 Annual Shareholder Meeting Date
July 30, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/vivosim-labs-sets-2026-annual-shareholder-meeting-date?utm_source=marketbeat.com&utm_medium=referral
VivoSim Labs, Inc. (VIVS)
July 28, 2026  |  ca.finance.yahoo.comhttps://ca.finance.yahoo.com/quote/VIVS/press-releases/
VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services
July 21, 2026  |  financialpost.comF
VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330426/37000/en/vivosim-enters-china-with-first-commercial-sales-of-namkind-toxicology-screening-and-efficacy-testing-services.html
VivoSim Labs Earnings Estimates, EPS & Revenue | NASDAQ:VIVS
July 16, 2026  |  benzinga.comhttps://www.benzinga.com/quote/VIVS/earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bullfrog AI stock logo

Bullfrog AI NASDAQ:BFRG

$0.62 -0.01 (-1.72%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$0.61 -0.01 (-1.86%)
As of 10/2/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

Bionano Genomics stock logo

Bionano Genomics NASDAQ:BNGO

$1.48 -0.09 (-5.73%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$1.53 +0.05 (+3.11%)
As of 10/2/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Harvard Bioscience stock logo

Harvard Bioscience NASDAQ:HBIO

$8.34 +0.21 (+2.58%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$8.33 -0.01 (-0.10%)
As of 10/2/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

VivoSim Labs stock logo

VivoSim Labs NASDAQ:VIVS

$0.20 -0.01 (-5.35%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$0.20 +0.00 (+0.81%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas